Results 131 to 140 of about 51,885 (293)
British Journal of Clinical Pharmacology, EarlyView.Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Evaluation of the relationship between the level of addiction and exhaled carbon monoxide levels with QT dispersion in smokers. [PDF]
Tob Induc Dis, 2021 Keskin G, Karaman ST, Basat O.
europepmc +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh +5 more
wiley +1 more source
Use of antiemetics in early pregnancy 2012–2022: A cross‐sectional study
British Journal of Clinical Pharmacology, EarlyView.Aim Nausea and vomiting in pregnancy impact quality of life, yet many pregnant women feel dismissed by healthcare professionals, despite the safety of first‐line antiemetic treatments for both mother and fetus. Therefore, this study aims to describe the prevalence of patient‐reported antiemetic use in early pregnancy in Copenhagen, Denmark, the changes
Katrine Bak Wraae +6 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert +6 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval +6 more
wiley +1 more source
Кардиоваскулярная терапия и профилактика, 1970 Aim. To assess the role of genetic factors in coronary atherosclerosis progression and myocardial electric instability development among patients with coronary heart disease (CHD) undergoing endovascular interventions. Material and methods.
Yu. I. Afanasiev +2 more
doaj
BMEMat, EarlyView.This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam +4 more
wiley +1 more source